The Company’s main strengths are: (i) a very new product portfolio, following the launch of six new products in the last two years; (ii) a benchmark product, Bemiparin, with good sales prospects, both in Spain and elsewhere; (iii) a contract manufacturing business with high value-added; and (iv) a sound, low-risk R&D division, with projects in very advanced phases that will be the Company’s future growth engine.
EnglishRead time: 1 min
You must select the acceptance of the agreement on compliance with the established restrictions.
Access to this information is limited to certain authorized persons who are resident and physically present in jurisdictions outside the United States, Canada, Australia and Japan.
We regret that, due to regulatory restrictions, we are unable to provide you with access to this section of our website.